- Cal-Bay International, Inc. (PINKSHEETS: CBYI) Puts Together Big Day of Volume but Share Price Slides
- Pacific Clean Water Technologies, Inc. (OTCQB: PCWT) Attracting Attention but Not All of it is Positive
- Is Axiologix, Inc. (PINKSHEETS: AXLX) Any Closer to Completing Targeted Acquisitions?
- With Financing Secured Will PacWest Equities, Inc. (PINKSHEETS: PWEI) Finally Monetize Solar Line of CIGS Manufacturing Technology?
- What Will the Future Bring for Seven Arts Entertainment Inc. (OTCQB: SAPX)?
OTC Equity Archives
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
Tagsaapl advertising amex apple basic materials biopharmaceutical biotechnology cancer capital goods china cloud computing copper diabetes drilling energy energy stocks exploration facebook fda gas gold gold mining google healthcare investors ipad iphone medical marijuana mining mobile NASDAQ natural gas nyse oil oil and gas otcbb penny stock penny stocks petroleum pharmaceutical Pink Sheets pinksheets silver sprint stocks
OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.
Registration to our newsletter is FREE, Join today by entering your email below!
Tag Archives: biopharmaceutical
On Tuesday shares of MultiCell Technologies, Inc. (PINKSHEETS: MCET) opened at 0.0034, a nice jump from their previous close of 0.0020, but the day would offer even more surprises for shareholders as the biopharmaceutical company surged to a high of … Continue reading
Can Dynavax Technologies Corporation (NASDAQ: DVAX) Overcome Safety Questions with Hepatitis B Vaccine and Get FDA Approval?
After sinking to a 52-week low of 2.22 on November 16, 2012 following an FDA Advisory Committee’s opinion that the data they reviewed regarding the hepatitis-B vaccine Heplisav was insufficient to demonstrate safety shares of Dynavax Technologies Corporation (NASDAQ: DVAX) … Continue reading
Can Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) Advance Cancer Drug into Phase III Trial Following Internal Review?
An internal review prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA may have saved Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) as shares of the biopharmaceutical company that develops first-in-class … Continue reading
Trading volume in Lexicon Pharmaceuticals (NASDAQ: LXRX) spiked on Monday, closing the last trading day of 2012 with more than 6.7 million shares moving hands while the share price of the biopharmaceutical company, which focuses on discovering breakthrough treatments for … Continue reading
Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) have been getting pounded on Friday following yesterday’s announcement that their lead product candidate HEPLISAV, an adult hepatitis B vaccine, failed to gain the support of an FDA advisory committee concerning safety issues. … Continue reading
Shares of Pain Therapeutics Inc. (NASDAQ: PTIE) continue to take a beating following news that their lead drug candidate Remoxy will be subjected to further tests before Pfizer agrees to seek FDA approval for the pain medication. Just yesterday shares … Continue reading
Busy Month for BioLine RX Ltd. (NASDAQ: BLRX) Has Biopharmaceutical Development Company on the Radar of Investors
After closing last week at 2.32 shares of BioLine RX Ltd. (NASDAQ: BLRX) jumped to a high of 2.85 on Monday with heavy trading volume following news that the biopharmaceutical development company had received from the United States Patent and … Continue reading
To say that ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) has been building momentum since their September 5, 2012 press release regarding the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP) … Continue reading
Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) have spiked to a high of 5.47 today and while they have slipped back down around the 5.24 level they are considerably higher than the 4.04 at which they opened the day. Along … Continue reading
With Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Affecting Reverse Stock Split Have They Bought Enough Time for Treatment of AML in Elderly?
Needing to boost their share price to satisfy the 1.00 minimum bid price requirement for continued listing on the NASDAQ Global Market, Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced a 1-for-7 reverse stock split on Friday and on Monday that split … Continue reading